Articles - Therapy, Safety and Efficacy Options

This cross-sectional study highlights the significant impact of moderate-to-severe atopic dermatitis (AD) on quality of life and economic burden among adult patients in the Asia-Pacific region. The findings reveal substantial impairment in quality of life, with high levels of pain, discomfort, and anxiety reported, alongside considerable annual costs associated with the condition. The study emphasizes the need for proactive management of AD and its comorbidities to alleviate this burden.

This study compares the perspectives of patients with atopic dermatitis and dermatologists in the Asia-Pacific region regarding treatment goals and communication. While both groups largely agree on treatment objectives, patients prioritize prevention of exacerbations and minimizing side effects more than dermatologists, and a notable percentage of patients expressed dissatisfaction with communication despite overall satisfaction with treatment. The findings highlight areas for improvement in patient-centered care.

This study aims to develop highly accurate machine learning models using automated machine learning (AutoML) to predict necessary therapy changes and identify factors influencing disease progression in patients with psoriasis vulgaris and psoriatic arthritis. The results indicate that specific patient features, such as initial therapeutic agents and quality of life changes, significantly impact treatment decisions and disease outcomes, ultimately enhancing clinical decision-making for improved patient care.

The research emphasizes the benefits of a multidisciplinary approach in managing atopic dermatitis (AD), a chronic inflammatory skin disorder that significantly impacts patients' quality of life. By accurately assessing individual risk profiles and enhancing patient-physician decision-making, this approach aims to improve treatment outcomes and overall care for patients with moderate-to-severe AD. The review calls for more data to establish standardized patient profiles and strategies for effective AD management.

Ustekinumab is an interleukin 12/23 inhibitor approved for moderate-to-severe plaque psoriasis and psoriatic arthropathy, and this review highlights its dermatological implications and applications. The findings indicate that ustekinumab is effective not only for psoriasis but also for various other dermatological conditions, including hidradenitis suppurativa and alopecia areata, and is particularly beneficial for childhood psoriasis and adult patients with concurrent Crohn’s disease.

The study explores the acceptability of 'as needed' biologic therapy for psoriasis among patients and clinicians, revealing that 67% of patients and 78% of clinicians support this approach. Both groups recognize its potential to reduce treatment burden and enhance patient ownership of care, while also identifying challenges related to medication logistics and disease management. The findings suggest a need for further assessment of the clinical effectiveness and cost-effectiveness of this treatment strategy.

The research discusses the development of new oral and topical small-molecule treatments for moderate-to-severe psoriasis, highlighting the approval of deucravacitinib, an oral Tyk2 inhibitor, and topical agents like tapinarof and roflumilast. It emphasizes the ongoing efforts to improve the efficacy and safety of these therapies in light of recent advances in understanding psoriasis pathogenesis.

This observational study analyzed treatment regimens and effectiveness for psoriasis among 407 patients in Southeast China, revealing that first-time diagnosed patients had a higher treatment response rate compared to those previously treated. The findings indicate lower response rates in real-world settings compared to clinical trials, highlighting unmet needs in psoriasis management and suggesting that combination and rotational strategies may enhance outcomes for unresponsive patients.

This systematic review examines the various methotrexate dosing regimens for treating atopic dermatitis, highlighting the lack of consensus and the risks of underdosing or overdosing. It summarizes findings from five randomized controlled trials and 21 guidelines, noting that while dosing varies, all studies showed efficacy in improving symptoms. The review serves as a resource for clinicians and aims to inform future consensus on dosing guideline

Abrocitinib demonstrated significant efficacy in improving skin clearance and reducing itch in patients with moderate-to-severe atopic dermatitis over a long-term period of up to 48 weeks, with approximately 52% achieving clear or almost clear skin and 82% showing substantial improvement in eczema severity. The safety profile was manageable, with common treatment-emergent adverse events including nasopharyngitis and nausea.

The research reviews a treat-to-target strategy and management algorithm for atopic dermatitis in light of recent systemic treatment approvals. It also identifies areas for further refinement and development within this evolving therapeutic landscape.

The research paper discusses modern pharmacologic interventions for pediatric atopic dermatitis (AD), highlighting the emergence of targeted treatments like dupilumab and JAK inhibitors as significant advancements. It reviews various topical and systemic therapies, including experimental agents, and proposes an updated therapeutic approach while emphasizing the need for further trials involving pediatric patients to better understand these emerging treatments.

The research addresses the challenges in managing psoriasis, particularly in difficult-to-treat areas, highlighting the limitations of current clinical scores in assessing disease severity. It suggests that integrating specialized scores like PSSI, NAPSI, and ESIF into existing methods could improve evaluation, proposing either using the highest score or adding a correction factor to enhance accuracy.

Benvitimod is an effective topical treatment for mild to moderate psoriasis, demonstrating significant improvements in various efficacy measures compared to placebo in a meta-analysis of six randomized controlled trials involving 1,925 patients. While the drug showed a higher incidence of adverse events, the risk of serious adverse events was non-significant, indicating a need for further large-scale studies to better assess its safety.

The review discusses the current state and future prospects of topical treatments for atopic dermatitis (AD), highlighting the limitations of existing therapies like topical corticosteroids and calcineurin inhibitors due to safety concerns. It notes that over 30 new topical compounds are in development, with some already FDA-approved, and emphasizes the need for larger, long-term studies to assess their efficacy and safety compared to current treatments.

This review addresses the challenges in diagnosing and treating pediatric psoriasis, highlighting the limited number of approved medications and the difficulties children face in accessing treatment. It emphasizes the need for clinicians to carefully consider the risks and benefits of available therapies, as pediatric psoriasis is often underrecognized and undertreated.

The research highlights the systemic impact of atopic dermatitis (AD), which affects up to 20% of children and can lead to comorbidities like asthma and food allergies. It emphasizes the importance of early therapy to restore the skin barrier and tailor treatments based on individual patient profiles, suggesting that a precision medicine approach could improve long-term management of AD and its associated conditions.

Atopic dermatitis (AD) is a prevalent skin condition that significantly affects patient health and quality of life, with recent advancements in understanding its pathogenesis leading to new therapeutic options. The review highlights the comorbidities associated with AD, including increased cardiovascular risk and adverse mental health outcomes, as well as the evolution of both topical and systemic treatments.